Data Sheet (Cat.No.T15642)

TargetMol

KAG-308

Chemical Properties



CAS No. : 1215192-68-9

Formula: C24H30F2N4O3

Molecular Weight: 460.52

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	KAG-308 is an effective selective and orally active agonist of the EP4 receptor (Ki: 2.57 nM and EC50: 17 nM for human EP4 receptor), more selective over EP1, EP2, EP3, and IP receptor. KAG-308 suppresses colitis and promotes histological mucosal healing, which potently inhibits TNF-α production.
Targets(IC50)	Prostaglandin Receptor
In vitro	KAG-308 shows effective agonist activity for human and mouse EP4 (EC50: 0.15 nM and 1.0 nM, respectively in the dual luciferase reporter assay). KAG-308 shows a Ki and EC50 values of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over human EP1 (Ki, 1410 nM; EC50, 1000 nM), EP2 (Ki, 1540 nM; EC50, 1000 nM), EP3 (Ki, 32.4 nM; EC50, 160 nM) and IP receptor (Ki, 52.9 nM; EC50, >10000 nM) [1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1715 mL	10.8573 mL	21.7146 mL
5 mM	0.4343 mL	2.1715 mL	4.3429 mL
10 mM	0.2171 mL	1.0857 mL	2.1715 mL
50 mM	0.0434 mL	0.2171 mL	0.4343 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Watanabe Y, et al. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. Eur J Pharmacol. 2015 May 5; 754:179-89.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481